- |||||||||| Flutiform (fluticasone/formoterol) / Kyorin, Mundipharma, Vectura, Sanofi, Breo Ellipta (fluticasone furoate / vilanterol) / GSK, Innoviva
Observational data, Retrospective data, Journal: Treatment persistence and exacerbations in patients with asthma initiating treatment with inhaled corticosteroids and beta-adrenergic agonists: retrospective cohort study. (Pubmed Central) - Apr 28, 2022 Patients undergoing treatment with FP/FORM and FF/VI versus FP/SAL, BDP/FORM and BUD/FORM were associated with greater treatment adherence (persistence, MPR) and lower rates of exacerbations. However, further studies will be needed to strengthen the consistency of the results.
- |||||||||| dexamethasone / Generic mfg.
Journal: Oncocytic adrenocortical neoplasm with undetermined malignant potential and autonomous cortisol secretion. (Pubmed Central) - Apr 28, 2022 Serum cortisol was not suppressed after 1 mg dexamethasone (31.5 µg/dL) and adrenocorticotrophic hormone was not detectable (<1.0 pg/mL)...These kinds of tumours can only be definitively diagnosed postsurgically using the Lin-Weiss-Bisceglia system. Although they have better prognosis compared with adrenocortical carcinomas and do not require chemotherapy, patients should be closely monitored to identify recurrence promptly.
- |||||||||| dexamethasone / Generic mfg., olanzapine / Generic mfg.
Retrospective data, Journal, CINV: Analysis of Chemotherapy-Induced Nausea and Vomiting during Chemotherapy for Gastric Cancer (Pubmed Central) - Apr 28, 2022 Although they have better prognosis compared with adrenocortical carcinomas and do not require chemotherapy, patients should be closely monitored to identify recurrence promptly. During first-line chemotherapy for gastric cancer, 3 antiemetic agents were used in 94% of cases, and the complete control rate of CINV was 67.8%.
- |||||||||| hydrocortisone / Generic mfg.
Retrospective data, Journal: Endocrinological aspects of pituitary adenoma surgery in Europe. (Pubmed Central) - Apr 28, 2022 Routine postoperative hydrocortisone replacement therapy is administered in 147 centers (58.6%)...Pretreatment for ACTH-secreting adenomas is routinely used in 21% of centers. This survey may serve as plea for neurosurgical care centralization of hormone-secreting adenomas.
- |||||||||| mometasone furoate / Generic mfg.
Journal: Triplet fusion upconversion nanocapsules for volumetric 3D printing. (Pubmed Central) - Apr 28, 2022 Upconversion is introduced to the resin by means of encapsulation with a silica shell and solubilizing ligands. We further introduce an excitonic strategy to systematically control the upconversion threshold to support either monovoxel or parallelized printing schemes, printing at power densities several orders of magnitude lower than the power densities required for two-photon-based 3D printing.
- |||||||||| dexamethasone / Generic mfg.
Journal: Based on Unmodified Aptamer-Gold Nanoparticles Colorimetric Detection of Dexamethasone in Food. (Pubmed Central) - Apr 28, 2022 To explore the interaction mechanism between aptamer and DEX, molecular docking and molecular dynamics simulations were applied to probe intermolecular interactions and structures of the complex. The establishment of aptamer-based sensors effectively avoids the antibody screening response, with a cost-efficient, excellent selective and great potential in DEX determination.
- |||||||||| iberdomide (CC-220) / BMS
Trial primary completion date, Combination therapy, Monotherapy: CC-220-MM-001: A Study to Determine Dose, Safety, Tolerability, Drug Levels, and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Participants With Multiple Myeloma (clinicaltrials.gov) - Apr 28, 2022 P1b/2a, N=532, Recruiting, The establishment of aptamer-based sensors effectively avoids the antibody screening response, with a cost-efficient, excellent selective and great potential in DEX determination. Trial primary completion date: Apr 2022 --> Apr 2026
- |||||||||| dexamethasone / Generic mfg.
Journal: Rationale and design of the CORE (COrticosteroids REvised) study: protocol. (Pubmed Central) - Apr 28, 2022 P1 Therefore, this study aims to re-examine the clinical bioequivalence and dose effects of the most widely used synthetic corticosteroids, prednisolone and dexamethasone...The results of this study will be submitted for publication in peer-reviewed journals. ClinicalTrials.gov (Identifier: NCT04733144), and in the Dutch trial registry (NL9138).
- |||||||||| dexamethasone / Generic mfg.
Journal: Recalibrating Interpretations of Aldosterone Assays Across the Physiologic Range: Immunoassay and Liquid Chromatography-Tandem Mass Spectrometry Measurements Under Multiple Controlled Conditions. (Pubmed Central) - Apr 28, 2022 Normotensive volunteers underwent prospective characterization of aldosterone production by immunoassay and LC-MS/MS during 4 conditions (n = 188): oral sodium suppression and restriction (to assess angiotensin II-mediated aldosterone production) and dexamethasone suppression and cosyntropin stimulation (to assess ACTH-mediated aldosterone production)...Aldosterone measurements are substantially lower by LC-MS/MS than immunoassay across the full physiologic range, especially when aldosterone levels were less than 20 ng/dL. These findings highlight the need to recalibrate diagnostic interpretations when measuring aldosterone via LC-MS/MS and provide insights into potential biologic causes of assay differences.
- |||||||||| fluticasone propionate/salmeterol xinafoate inhalation powder / Generic mfg.
@GSK whyyyyyyy (advair) (Twitter) - Apr 28, 2022
- |||||||||| methylprednisolone acetate / Generic mfg.
Enrollment change, Trial withdrawal: Phenol Neurolysis of Genicular Nerves for Chronic Knee Pain (clinicaltrials.gov) - Apr 28, 2022 P4, N=0, Withdrawn, These findings highlight the need to recalibrate diagnostic interpretations when measuring aldosterone via LC-MS/MS and provide insights into potential biologic causes of assay differences. N=40 --> 0 | Recruiting --> Withdrawn
- |||||||||| Sarclisa (isatuximab-irfc) / Sanofi
Trial completion date, Trial primary completion date, Combination therapy: Isatuximab in Combination With Novel Agents in RRMM - Master Protocol (clinicaltrials.gov) - Apr 28, 2022 P1/2, N=66, Recruiting, Trial completion date: Mar 2022 --> Mar 2023 | Trial primary completion date: Jan 2022 --> Jan 2023 Trial completion date: Aug 2026 --> Apr 2027 | Trial primary completion date: Aug 2026 --> Apr 2027
- |||||||||| dexamethasone / Generic mfg., ceftriaxone / Generic mfg.
Prevention of radiation-induced rectal injuries with perirectal blocks in radiation therapy. () - Apr 28, 2022 - Abstract #ASCO2022ASCO_5493; Parametrial blocks during brachytherapy improve the status of tissues of the small pelvis which, in turn, prevents radiation damage, contributes to the timely radiotherapy completion, and improves the treatment effectiveness and the quality of life of patients. This technique is especially relevant in view of the increasing number of diseases that disrupt microcirculation, and hence the oxygenation of tissues, causing tumor radio- and chemoresistance.
- |||||||||| relacorilant (CORT125134) / Corcept Therap
ROSELLA: A phase 3 study of relacorilant in combination with nab-paclitaxel versus investigator’s choice in advanced, platinum-resistant, high-grade epithelial ovarian, primary peritoneal, or fallopian-tube cancer. (Available On Demand; 486b) - Apr 28, 2022 - Abstract #ASCO2022ASCO_5448; Randomization is stratified by prior lines of therapy (1 vs > 1), region of world (North America vs Europe), and prior bevacizumab (yes/no)...The primary study endpoint is PFS by blinded independent central review. Key secondary endpoints include overall survival, PFS by investigator, overall response rate, best overall response, DOR, clinical benefit rate, safety, quality of life, CA-125, pharmacodynamics, and pharmacokinetics.
- |||||||||| clindamycin phosphate / Generic mfg.
The PROTECT Study: A phase II, open-label trial of prophylactic skin toxicity therapy with clindamycin and triamcinolone in patients with glioblastoma treated with tumor-treating fields. (Available On Demand; 416b) - Apr 28, 2022 - Abstract #ASCO2022ASCO_4439; P2 The first patient was enrolled on October 21, 2020 and hitherto, 8 patients have been consented. Participating sites include Memorial Sloan Kettering Cancer Center, Columbia University Medical Center, Tufts University Medical Center, Northwestern University, Washington University, University of Cincinnati, and John Theurer Cancer Center - Hackensack Meridian Health.
- |||||||||| dexamethasone / Generic mfg., lenalidomide / Generic mfg.
Preliminary efficacy of optimal pharmacotherapy and patient views in multiple myeloma. () - Apr 28, 2022 - Abstract #ASCO2022ASCO_4215; Among the survey respondents, socioeconomic status was unclear which may influence patients’ expectations and preferences for treatment decisions in MM. Insufficient reporting in the qualitative studies makes it unclear how a patient’s treatment decisions changes over time.
- |||||||||| lenalidomide / Generic mfg., carfilzomib / Generic mfg.
Addition of carfilzomib as a third agent in lenalidomide-refractory multiple myeloma: Switching from doublet to triplet. () - Apr 28, 2022 - Abstract #ASCO2022ASCO_4208; ISS was equally distributed, and all patients had previously been treated with bortezomib and IMIDs, and were refractory to this agents...Carfilzomib was well tolerated, with grade 2 anemia in 39%(16/41) of patients, successfully managed by ESAs, without necessity of blood transfusions; 29% (12/41) grade 3-4 neutropenia (pegfilgrastim in primary prophylaxis was given, no ospedalization was required, no septic shocks were observed); 34% (14/41) grade 2, 21% (9/41) grade 3 and 12% (5/41) grade 4 thrombocytopenia, without hemorrhagic events and transfusion-dependency... Carfilzomib-Lenalidomide-Dexamethasone has shown significant efficacy in a particularly severe setting of patients, relapsed and refractory to all available therapeutic resources, also lenalidomide, and it could be considered as a bridge to a second autologous or allogenic SCT.
- |||||||||| bortezomib / Generic mfg., dexamethasone / Generic mfg., bendamustine / Generic mfg.
Chemo or chemo-free regimens in heavily pretreated multiple myeloma? Role of bendamustine-bortezomib-dexamethasone (BVD) in NOVEL agents' era. () - Apr 28, 2022 - Abstract #ASCO2022ASCO_4204; 36-82), median age at start of treatment 63.6 years (r.37-86) treated with several lines of treatments (median 6, r. 2-11), every refractory to all the drugs previously received (also Bortezomib), received BVD (B 90 mg/sqm days 1,2; V 1.3 mg/sqm days 1,4,8,11, D 20 mg days 1,2,4,5,8,9,11,12, Pegfilgrastim day +4) every 28 days, until progression...Eight patients have surprisingly achieved a notable PR after failure of novel agents (i.e. Carfilzomib, Daratumumab and Pomalidomide). The triplet Bendamustine-Bortezomib-Dexamethasone has shown significant efficacy in a particularly severe setting of patients, relapsed and refractory to all available therapeutic resources, and, in particular cases, it could be considered as a bridge to a second autologous or allogenic SCT, also after failure of novel agents.
- |||||||||| teclistamab (JNJ-64007957) / Genmab, J&J, Xpovio (selinexor) / Karyopharm, Menarini, FORUS Therap
Matching-adjusted indirect comparison (MAIC) of teclistamab (tec) versus selinexor-dexamethasone (sel-dex) for the treatment of patients (pts) with triple-class exposed (TCE) relapsed/refractory multiple myeloma (RRMM). () - Apr 28, 2022 - Abstract #ASCO2022ASCO_4199; P2, P2b However, there was a trend towards improved PFS in patients with HR abnormalities other than 1q+. In this MAIC, tec showed significantly improved efficacy over sel-dex for all outcomes except PFS, which was numerically in favor of tec, highlighting its potential as a highly effective treatment option for pts with TCE RRMM who received ≥3 prior LOT.
- |||||||||| Darzalex (daratumumab) / J&J, Sarclisa (isatuximab-irfc) / Sanofi
A systematic review on smoldering multiple myeloma: Whether treatment is beneficial. () - Apr 28, 2022 - Abstract #ASCO2022ASCO_4194; However, based on the data analyzed from the seven clinical trials, we advocate for early therapeutic intervention in high-risk SMM patients. There are multiple ongoing clinical trials to answer whether we should treat SMM or not.
- |||||||||| elranatamab (PF-06863135) / Pfizer, Darzalex Faspro (daratumumab/hyaluronidase) / J&J
MagnetisMM-5: An open-label, multicenter, randomized phase 3 study of elranatamab as monotherapy and in combination with daratumumab in patients with relapsed/refractory multiple myeloma. (Available On Demand; 494a) - Apr 28, 2022 - Abstract #ASCO2022ASCO_4186; P3 MagnetisMM-5 is an open-label, multicenter, randomized phase 3 study designed to evaluate the efficacy and safety of subcutaneous (SC) elranatamab monotherapy and SC elranatamab + SC daratumumab in pts with relapsed/refractory MM who have received prior therapy, including lenalidomide and a proteasome inhibitor (PI)...In part 2, ̃450 pts will be stratified by prior lines of therapy (1 vs 2–3 vs ≥4) and prior treatment with anti-CD38 therapy (yes vs no) and enrolled in a 1:1:1 ratio to receive SC elranatamab or SC elranatamab + SC daratumumab or SC daratumumab + oral pomalidomide + oral dexamethasone...Key exclusion criteria include smoldering MM, plasma cell leukemia, amyloidosis, POEMS syndrome, stem cell transplant within 12 wk of enrollment, primary refractory MM, active, uncontrolled bacterial, fungal, or viral infections, previous treatment with BCMA-targeted therapy, anti-CD38 therapy within 6 mo of the first dose of study treatment, and previous pomalidomide therapy. MagnestisMM-5 will include sites in 28 countries.
- |||||||||| Darzalex (daratumumab) / J&J, teclistamab (JNJ-64007957) / Genmab, J&J
MajesTEC-3: Randomized, phase 3 study of teclistamab plus daratumumab versus investigator’s choice of daratumumab, pomalidomide, and dexamethasone or daratumumab, bortezomib, and dexamethasone in patients with relapsed/refractory multiple myeloma. (Available On Demand; 493a) - Apr 28, 2022 - Abstract #ASCO2022ASCO_4184; P1, P1b, P Adverse events (AEs) will be graded by Common Terminology Criteria for AEs v5.0, except for cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome, which will be graded by American Society for Transplantation and Cellular Therapy guidelines. The study opened in October 2021 and enrollment is ongoing.
- |||||||||| cevostamab (RG6160) / Roche
CAMMA 1: A multicenter phase Ib trial evaluating the safety, pharmacokinetics, and activity of cevostamab-containing regimens in patients with relapsed or refractory multiple myeloma. (Available On Demand; 491b) - Apr 28, 2022 - Abstract #ASCO2022ASCO_4181; P1 CAMMA 1 (NCT04910568) is an open-label, multicenter Phase Ib trial evaluating the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics of cevostamab-containing combination regimens (Arm B: cevostamab plus P and dexamethasone [d] [Pd]; Arm C: cevostamab plus Dd) in patients with R/R MM...The primary objective is to evaluate the safety and tolerability of cevostamab plus Pd, cevostamab plus Dd and cevostamab monotherapy. Secondary objectives include assessment of activity, PK, immunogenicity, and pharmacodynamic biomarkers.
|